Ads
related to: bortezomib indication- Glioma Treatment Option
Learn More About A Treatment
Option For Your Patients.
- Now Approved
Learn About a Newly Approved
Glioma Treatment Option.
- Access & Resources
Resources Are Available For
You and Your Patients
- FAQ Page
Visit Our FAQ Page To Answer
Your Questions About Treatment.
- Glioma Treatment Option
Search results
Results From The WOW.Com Content Network
Bortezomib, sold under the brand name Velcade among others, is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma. [4] This includes multiple myeloma in those who have and have not previously received treatment. [ 3 ]
Indication Date Approved in USA [14] Partner VELCADE: bortezomib Velcade is indicated for the front-line treatment of multiple myeloma and for patients with mantle cell lymphoma who have received at least 1 prior therapy. 05-13-2003
Bortezomib (Velcade) was approved in 2003. This was the first proteasome inhibitor approved for use in the U.S. Its boron atom binds the catalytic site of the 26S proteasome. [20] Carfilzomib (Kyprolis) was approved by the FDA for relapsed and refractory multiple myeloma in 2012 . [21]
Indications [1] [2] [4] Major toxicities [1] [2] [4] [5] 1. Cytotoxic antineoplastics: 1.01 Nucleoside analogues: Azacitidine: SC, IV: DNA methyltransferase inhibitor and incorporates itself into RNA, hence inhibiting gene expression. [6] Myelodysplastic syndromes, acute myeloid leukaemia and chronic myeloid leukaemia
Bortezomib/dexamethasone is a combination drug against multiple myeloma. [1] When bortezomib is used by the trade name Velcade, the combination is called Vel/Dex (or Vel-Dex or Veldex ). Bortezomib is a proteasome inhibitor and dexamethasone is a corticosteroid .
Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. [6] ...
Ad
related to: bortezomib indication